The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines

Authors: Peter L. Greenberg MD a , Leon E. Cosler RPh, PhD a , Salvatore A. Ferro a and Gary H. Lyman MD, MPH, FRCP(Edin) a
View More View Less
  • a From Stanford University Cancer Center, Stanford, California; Research Institute for Health Outcomes, Albany College of Pharmacy, Albany, New York; and Duke University and Duke Comprehensive Cancer Center, Durham, North Carolina.

Guidelines for management of patients with myelodysplastic syndromes (MDS) have been generated by the National Comprehensive Cancer Network (NCCN) Myelodysplastic Syndromes Panel. Because MDS is a heterogeneous spectrum of disorders, these patients have been categorized into prognostic subgroups, predominantly using the International Prognostic Scoring System (IPSS). Several drugs have been used to treat these patients, and their selection and sequential recommended use by the panel depend on disease characteristics and responses to treatment. Recombinant erythropoietin alfa and darbepoetin alfa have been the mainstay of therapy for treating anemia associated with MDS. The FDA has recently approved several other drugs for treating MDS, including azacytidine and decitabine for all stages of disease, lenalidomide for low-risk anemic patients with del(5q) chromosomal abnormality, and deferasirox for treating iron overload. For iron chelation, deferoxamine is also used occasionally. Treatment with immunosuppressive therapy (antithymocyte globulin and cyclosporin) has been therapeutically beneficial for a subset of younger patients with MDS. Because the financial cost of these therapies are substantial and have received only limited attention, this article evaluates the costs of specific drugs and their sequential use in the lower-risk IPSS (low and intermediate-1) subgroups based on the NCCN guidelines. Results estimate an average annual cost for potentially anemia-altering drugs of $63,577 per patient, ranging from $26,000 to $95,000, depending on the specific therapies. In patients for whom the therapies fail, annual costs for iron chelation plus red blood cell transfusions are estimated to average $41,412. The economic impact of drug therapy should be weighed against the patient's potential for improvement in clinical outcomes, quality of life, and transfusion requirements.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Peter Greenberg, MD, Hematology Division, Stanford University Cancer Center, 875 Blake Wilbur Drive, Room 2335, Stanford, CA 94305-5821. E-mail: peterg@stanford.edu
  • 1.

    Greenberg PL. Clinical and prognostic characterization of myelodysplastic syndromes. In: Greenberg PL, ed. Myelodysplastic Syndromes: Clinical and Biological Advances. 1st ed. Cambridge: Cambridge University Press; 2006:132.

    • Search Google Scholar
    • Export Citation
  • 2.

    Greenberg P, Cox C, LeBeau MM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:20792088.

  • 3.

    Greenberg PL, Bennett JM, Bloomfield CD. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 1, 2004. J Natl Compr Canc Netw 2003;1:456471.

    • Search Google Scholar
    • Export Citation
  • 4.

    Greenberg P, Battiwalla M, Bennett J. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 1, 2009. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed August 15, 2008.

    • Search Google Scholar
    • Export Citation
  • 5.

    Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:6771.

    • Search Google Scholar
    • Export Citation
  • 6.

    Negrin RS, Stein R, Vardiman J. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993;82:737743.

    • Search Google Scholar
    • Export Citation
  • 7.

    Gotlib J, Greenberg PL. Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy. In: Greenberg PL, ed. Myelodysplastic Syndromes: Clinical and Biological Advances. 1st ed. Cambridge: Cambridge University Press; 2006:209242.

    • Search Google Scholar
    • Export Citation
  • 8.

    Hellstrom-Lindberg E, Ahlgren T, Beguin Y. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92:6875.

    • Search Google Scholar
    • Export Citation
  • 9.

    Hellstrom-Lindberg E, Negrin R, Stein R. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99:344351.

    • Search Google Scholar
    • Export Citation
  • 10.

    Casadevall N, Durieux P, Dubois S. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104:321327.

    • Search Google Scholar
    • Export Citation
  • 11.

    Musto P, Lanza F, Balleari E. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204209.

    • Search Google Scholar
    • Export Citation
  • 12.

    Mannone L, Gardin C, Quarre MC. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006;133:513519.

    • Search Google Scholar
    • Export Citation
  • 13.

    Silverman LR, Demakos EP, Peterson BL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:24292440.

    • Search Google Scholar
    • Export Citation
  • 14.

    Kantarjian H, Issa JP, Rosenfeld CS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:17941803.

    • Search Google Scholar
    • Export Citation
  • 15.

    List A, Dewald G, Bennett J. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:14561465.

  • 16.

    Porter J, Galanello R, Saglio G. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008;80:168176.

    • Search Google Scholar
    • Export Citation
  • 17.

    Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739761.

  • 18.

    Payne KA, Desrosiers MP, Caro JJ. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 2007;47:18201829.

    • Search Google Scholar
    • Export Citation
  • 19.

    Kantarjian H, Oki Y, Garcia-Manero G. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:5257.

    • Search Google Scholar
    • Export Citation
  • 20.

    Raza A, Reeves JA, Feldman EJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:8693.

    • Search Google Scholar
    • Export Citation
  • 21.

    Sloand E, Wu C, Greenberg P. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:25052011.

    • Search Google Scholar
    • Export Citation
  • 22.

    The cost of blood: multidisciplinary consensus conference for a standard methodology. Transfus Med Rev 2005;19:6678.

  • 23.

    Cremieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000;18:27552761.

  • 24.

    Shander A, Hofmann A, Gombotz H. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007;21:271289.

    • Search Google Scholar
    • Export Citation
  • 25.

    Catlin A, Cowan C, Hartman M, Heffler S. National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood) 2008;27:1429.

    • Search Google Scholar
    • Export Citation
  • 26.

    Brown ML, Yabroff KR. Economic impact of cancer in the United States. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:202214.

    • Search Google Scholar
    • Export Citation
  • 27.

    Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40(8 Suppl):IV-104117.

    • Search Google Scholar
    • Export Citation
  • 28.

    Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 2007;4:643656.

  • 29.

    Kuderer NM, Dale DC, Crawford J. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:22582266.

    • Search Google Scholar
    • Export Citation
  • 30.

    Lyman GH, Berndt ER, Kallich JD. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005;8:149156.

  • 31.

    Berndt E, Crown W, Kallich J. The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics 2005;23:183192.

    • Search Google Scholar
    • Export Citation
  • 32.

    McKoy JM, Fitzner KA, Edwards BJ. Cost considerations in the management of cancer in the older patient. Oncology (Williston Park) 2007;21:851857; discussion 858, 860, 862 passim.

    • Search Google Scholar
    • Export Citation
  • 33.

    Liou SY, Stephens JM, Carpiuc KT. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 2007;27:381396.

    • Search Google Scholar
    • Export Citation
  • 34.

    Goss TF, Szende A, Schaefer C. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 2006;13 Suppl:1725.

    • Search Google Scholar
    • Export Citation
  • 35.

    Pavenski K, Quirt I. The real cost of iron chelation therapy. Transfusion 2007;47:17511752.

  • 36.

    CMS. Hospital outpatient PPS. Available at: http://www.cms.hhs.gov/HospitalOutpatientPPS/01_overview.asp#TopOfPage. Accessed August 15, 2008.

    • Search Google Scholar
    • Export Citation
  • 37.

    CMS. Medicare prescription drug plan cost estimator tool methodology. Medicare A. 2008; Available at: http://www.medicare.gov/medicarereform/Cost-Estimator-Tool-Methodology.pdf. Accessed August 15, 2008.

    • Search Google Scholar
    • Export Citation
  • 38.

    MedicareB. Payment allowance limits for Medicare Part B drugs. Cigna Government Services. Available at: https://www.cignagovernmentservices.com/partb/coverage/fees. Accessed August 15, 2008.

    • Search Google Scholar
    • Export Citation
  • 39.

    Malcovati L, Porta MG, Pascutto C. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:75947603.

    • Search Google Scholar
    • Export Citation
  • 40.

    Lyman GH. Time is money for both the healthy and the sick. Med Care 2005;43:637639.

  • 41.

    Rizzo JD, Somerfield MR, Hagerty KL. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132149.

    • Search Google Scholar
    • Export Citation
  • 42.

    Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129146.

    • Search Google Scholar
    • Export Citation
  • 43.

    Cosler LE, Calhoun EA, Agboola O, Lyman GH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24:488494.

    • Search Google Scholar
    • Export Citation
  • 44.

    Baldi G, D'Inca M, Saltini L. Cost/benefit relationship in 46 cases of myelodysplastic syndrome (RAEB and RAEB-T): a quality assurance analysis in clinical haematology. Haematologica 1993;78:291296.

    • Search Google Scholar
    • Export Citation
  • 45.

    Yabroff KR, Warren JL, Knopf K. Estimating patient time costs associated with colorectal cancer care. Med Care 2005;43:640648.

  • 46.

    Kolata G. Co-payments go way up for drugs with high prices. New York Times. April 14, 2008, 2008:A1

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 161 72 15
PDF Downloads 117 82 13
EPUB Downloads 0 0 0